Abstract
The blood-brain barrier (BBB) and blood-CSF barrier (BCSFB) represent the main interfaces between the central nervous system (CNS) and the peripheral circulation. Drug exposure to the CNS is dependent on a variety of factors, including the physical barrier presented by the BBB and the BCSFB and the affinity of the substrate for specific transport systems located at both of these interfaces. It is the aggregate effect of these factors that ultimately determines the total CNS exposure, and thus pharmacological efficacy, of a drug or drug candidate. This review discusses the anatomical and biochemical barriers presented to solute access to the CNS. In particular, the important role played by various efflux transporters in the overall barrier function is considered in detail, as current literature suggests that efflux transport likely represents a key determinant of overall CNS exposure for many substrates. Finally, it is important to consider not only the net delivery of the agent to the CNS, but also the ability of the agent to access the relevant target site within the CNS. Potential approaches to increasing both net CNS and target-site exposure, when such exposure is dictated by efflux transport, are considered.
Keywords: blood-brain barrier, blood-csf barrier, efflux transporters, central nervous system, p-glycoprotein, multidrug resistance associated protein
Current Drug Metabolism
Title: (Section B: Integrated Function of Drug Transporters In Vivo) Drug Transport at the Blood-Brain Barrier and the Choroid Plexus
Volume: 5 Issue: 1
Author(s): Candace L. Graff and Gary M. Pollack
Affiliation:
Keywords: blood-brain barrier, blood-csf barrier, efflux transporters, central nervous system, p-glycoprotein, multidrug resistance associated protein
Abstract: The blood-brain barrier (BBB) and blood-CSF barrier (BCSFB) represent the main interfaces between the central nervous system (CNS) and the peripheral circulation. Drug exposure to the CNS is dependent on a variety of factors, including the physical barrier presented by the BBB and the BCSFB and the affinity of the substrate for specific transport systems located at both of these interfaces. It is the aggregate effect of these factors that ultimately determines the total CNS exposure, and thus pharmacological efficacy, of a drug or drug candidate. This review discusses the anatomical and biochemical barriers presented to solute access to the CNS. In particular, the important role played by various efflux transporters in the overall barrier function is considered in detail, as current literature suggests that efflux transport likely represents a key determinant of overall CNS exposure for many substrates. Finally, it is important to consider not only the net delivery of the agent to the CNS, but also the ability of the agent to access the relevant target site within the CNS. Potential approaches to increasing both net CNS and target-site exposure, when such exposure is dictated by efflux transport, are considered.
Export Options
About this article
Cite this article as:
Graff L. Candace and Pollack M. Gary, (Section B: Integrated Function of Drug Transporters In Vivo) Drug Transport at the Blood-Brain Barrier and the Choroid Plexus, Current Drug Metabolism 2004; 5 (1) . https://dx.doi.org/10.2174/1389200043489126
DOI https://dx.doi.org/10.2174/1389200043489126 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transgenic Models in Allergic Responses
Current Drug Targets Clinical Queries Addressed in Patients with Systemic Autoimmune Diseases. Can Cardiovascular Magnetic Resonance Give the Final Solution?
Inflammation & Allergy - Drug Targets (Discontinued) Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Celastrol Inhibits Inflammatory Stimuli-Induced Neutrophil Extracellular Trap Formation
Current Molecular Medicine Preface
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Dimethyloxallyl Glycine-Incorporated Borosilicate Bioactive Glass Scaffolds for Improving Angiogenesis and Osteogenesis in Critical-Sized Calvarial Defects
Current Drug Delivery Hypersensitivity to Lamotrigine and Nonaromatic Anticonvulsant Drugs: A Review
Current Pharmaceutical Design Novel Approaches to the Therapy of Rheumatoid Arthritis based on an Understanding of Disease Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Blood Atherogenicity as a Target for Anti-atherosclerotic Therapy
Current Pharmaceutical Design Leukocytoclastic Vasculitis Associated with HHV6-A/ciHHV6-A and HHV6-B Coinfection in an Immunocompetent Woman
Endocrine, Metabolic & Immune Disorders - Drug Targets Measuring Vasculitis with Numbers: Outcome Scores
Current Rheumatology Reviews Role of Advanced Glycation End Products in Diabetic Neuropathy
Current Pharmaceutical Design Common and Uncommon Features of Rheumatoid Arthritis and Chronic Obstructive Pulmonary Disease: Clues to a Future Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Mediterranean Diet, Brain and Muscle: Olive Polyphenols and Resveratrol Protection in Neurodegenerative and Neuromuscular Disorders
Current Medicinal Chemistry Heme Oxygenase-Derived Carbon Monoxide Restores Vascular Function in Type 1 Diabetes
Drug Metabolism Letters Systemic Lupus Erythematosus-Related Interstitial Lung Disease
Current Rheumatology Reviews Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Current Medicinal Chemistry Substance P in Rheumatic Diseases
Current Rheumatology Reviews Clopidogrel and Aspirin in Cardiovascular Medicine: Responders or Not -- Current Best Available Evidence
Cardiovascular & Hematological Agents in Medicinal Chemistry Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging